Enhanced solubility and bioavailability of ranolazine by solid dispersion method in vitro and in vivo evaluation
A potential novel approach for cardiovascular diseases
Keywords:
ranolazine, solubility, BCS class, hydrophilic carriers, solid dispersion, solvent evaporation methodAbstract
Objective: This study aims to formulate solid dispersions incorporating ranolazine to enhance its aqueous solubility. Methodology: The poor aqueous solubility and permeability of BCS class II drug hamper their bioavailability when orally or topically administered. The present research study focused on formulating amorphous solid dispersions of ranolazine. The hydrophilic polymeric carriers like, HPMC, PEG 6000 and PVPK 30K, Soluplus were used in different ratio. Solid dispersions were prepared by employing modified solvent evaporation method. The prepared physical mixtures and solid dispersions were physico-chemically characterized using fourier transform infrared spectroscopy, scanning electron microscopy, powder x-ray diffractometry, drug content estimation by UV-spectrophotometric method. Result: Functional evaluation of ranolazine solid dispersions was carried out by solubility analysis, in-vitro dissolution studies and pharmacokinetics study. According to solubility studies, Soluplus showed the highest solubility profile among the polymers tested. An optimized ranolazine containing solid dispersions formulation composed of Soluplus at 1:2.5 ratio had 10 fold (41.21 ± 0.35μg/mL) higher solubility and dissolution over that of pure ranolazine (~ 3.92 ± 0.06μg/mL) and physical mixture (~ 4.51 ± 0.32μg/mL). In-vitro dissolution studies revealed that there was increase in solubility of drug and enhanced dissolution rate in solid dispersions compared to physical mixtures respectively.
Downloads
References
Rinartha, K., Suryasa, W., & Kartika, L. G. S. (2018). Comparative Analysis of String Similarity on Dynamic Query Suggestions. In 2018 Electrical Power, Electronics, Communications, Controls and Informatics Seminar (EECCIS) (pp. 399-404). IEEE.
Rahmadeni, A. S. ., Hayat, N. ., Alba, A. D. ., Badri, I. A. ., & Fadhila, F. . (2020). The relationship of family social support with depression levels of elderly in 2019 . International Journal of Health & Medical Sciences, 3(1), 111-116. https://doi.org/10.31295/ijhms.v3n1.188
Giri TK, Kumar K, Alexander A, Ajazuddin, Badwaik H, Tripathi DK. A novel and alternative approach to controlled release drug delivery system based on solid dispersion technique. Bull Fac Pharmacy, Cairo Univ 2012;50:147–159 . https://doi.org/10.1016/j.bfopcu.2012.07.002
Pandey R, Bhairam M, Shukla SS, Gidwani B. Colloidal and vesicular delivery system for herbal bioactive constituents. DARU, J Pharm Sci 2021;29:415–438. https://doi.org/10.1007/s40199-021-00403-x
Monschke M, Kayser K, Wagner KG. Influence of Particle Size and Drug Load on Amorphous Solid Dispersions Containing pH-Dependent Soluble Polymers and the Weak Base Ketoconazole. AAPS PharmSciTech 2021;22:1–11 . https://doi.org/10.1208/s12249-020-01914-7
Lakshman D, Chegireddy M, Hanegave GK, Sree KN, Kumar N, Lewis SA, Dengale SJ. Investigation of drug-polymer miscibility, biorelevant dissolution, and bioavailability improvement of Dolutegravir-polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solid dispersions. Eur J Pharm Sci 2020;142:105137. https://doi.org/10.1016/j.ejps.2019.105137
Telange DR, Ukey SA, Hemke AT, Umekar MJ, Pethe AM, Kharkar PS. LIPOID SPC-3-Based Coprecipitates for the Enhancement of Aqueous Solubility and Permeability of Ranolazine. J Pharm Innov 2021;16:643–658. https://doi.org/10.1007/s12247-020-09477-7
Bisht D, Verma D, Mirza MA, Anwer MK, Iqbal Z. Development of ethosomal gel of ranolazine for improved topical delivery: In vitro and ex vivo evaluation. J Mol Liq 2017;225:475–481 . https://doi.org/10.1016/j.molliq.2016.11.114
Chidella KS, Dasari VB, Anireddy J. Simultaneous and Trace Level Quantification of Five Potential Genotoxic Impurities in Ranolazine Active Pharmaceutical Ingredient Using LC-MS/MS. Am J Anal Chem 2021;12:1–14. https://doi.org/10.4236/ajac.2021.121001
Nunoi Y, Kambayashi R, Goto A, Hagiwara-Nagasawa M, Chiba K, Izumi-Nakaseko H, Kawai S, Takei Y, Matsumoto A, Watanabe Y, Sugiyama A. In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of I Na,L plus I Kr inhibitor ranolazine using the halothane-anesthetized dogs. Heart Vessels 2021;36:1088–1097 . https://doi.org/10.1007/s00380-021-01830-1
Kini A, Patel SB. Phase behavior, intermolecular interaction, and solid state characterization of amorphous solid dispersion of Febuxostat. Pharm Dev Technol 2017;22:45–57 . https://doi.org/10.3109/10837450.2016.1138130
Huang Y, Dai W-G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B 2014;4:18–25. https://doi.org/10.1016/j.apsb.2013.11.001
Kim NA, Oh HK, Lee JC, Choi YH, Jeong SH. Comparison of solubility enhancement by solid dispersion and micronized butein and its correlation with in vivo study. J Pharm Investig 2021;51:53–60 . https://doi.org/10.1007/s40005-020-00486-9
Gidwani B, Vyas A, Kaur CD. Cytotoxicity and pharmacokinetics study of nanostructured lipid carriers of mechlorethamine: Preparation, optimization and characterization. Part Sci Technol 2020;38:23–33 . https://doi.org/10.1080/02726351.2018.1536685
Vieira R, Severino P, Nalone LA, Souto SB, Silva M, Lucarini M, Durazzo A, Santini A. Sucupira Oil-Loaded Nanostructured Lipid Carriers (NLC): Lipid Screening, Factorial Design, Release Profile, and Cytotoxicity 2020; 029:1–22
Gidwani B, Vyas A Pharmacokinetic study of solid-lipid-nanoparticles of altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and oral bioavailability. Int J Biol Macromol 2017;101:24–31. https://doi.org/10.1016/j.ijbiomac.2017.03.047
Telange DR, Patil AT, Pethe AM, Fegade H, Anand S, Dave VS. Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential. Eur J Pharm Sci 2017;108:36–49 . https://doi.org/10.1016/j.ejps.2016.12.009
Baghel P, Roy A, Verma S, Satapathy T, Bahadur S. Enhancement of solubility of paclitaxel by applying factorial design. Curr Med Res Pract 2021;11:216-24
Dhore PW, Dave VS, Saoji SD, Gupta D, Raut NA. Influence of carrier (Polymer) type and drug-carrier ratio in the development of amorphous dispersions for solubility and permeability enhancement of ritonavir. J Excipients Food Chem 2017; 8:75–92
Choudhary A, Rana AC, Aggarwal G, Kumar V, Zakir F. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharm Sin B 2012;2:421–428. https://doi.org/10.1016/j.apsb.2012.05.002
Shrivastava S, Gidwani B, Kaur CD. Development of mebendazole loaded nanostructured lipid carriers for lymphatic and in-vivo evaluation. Part Sci Technol 2020;0:1–11 . https://doi.org/10.1080/02726351.2020.1750515
Chavan RB, Lodagekar A, Yadav B, Shastri NR. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study. Drug Deliv Transl Res 2020;10:4:903-918. doi: 10.1007/s13346-020-00775-8. PMID: 32378174.
Adebisi AO, Kaialy W, Hussain T, Al-hamidi H, Nokhodchi A, Conway BR, Asare-addo K. Freeze-dried crystalline dispersions: Solid-state, triboelectrification and simultaneous dissolution improvements. Journal of Drug Delivery Science and Technology 2021; 61: 102173. https://doi.org/10.1016/j.jddst.2020.102173.
Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ohike A, Ibuki R, Higaki K, Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J Control Release. 2005;108(2-3):386-95. doi: 10.1016/j.jconrel.2005.08.024.
Truong DH, Tran TH, Ramasamy T, Choi JY, Choi H, Yong CS, Kim JO. Preparation and Characterization of Solid Dispersion Using a Novel Amphiphilic Copolymer to Enhance Dissolution and Oral Bioavailability of Sorafenib. Powder Technol 2015;283: 260-265. https://doi.org/10.1016/j.powtec.2015.04.044
Kamble RN, Gaikwad S, Maske A, Patil SS. Fabrication of electrospun nanofibres of BCS II drug for enhanced dissolution and permeation across skin. J Adv Res 2016;7:483–489 . https://doi.org/10.1016/j.jare.2016.03.009
Monika B, Amit R, Sanjib B, Alisha B, Mihir P. Transdermal Drug Delivery System with Formulation and Evaluation Aspects : Overview. RJPT, 2012; 5:1168–1176
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
